Home > Haematological Malignancies > Lymphoma
    • FILTER YOUR SEARCH
    Content Type:

    • Lymphoma

    An Introduction to Lymphoma

    Lymphoma is one of the ten most common malignancies worldwide. While some lymphomas are curable, the treatment of relapsed and refractory disease remains a substantial challenge. Recent advances have led to the development of a number of new treatment strategies, including novel antibodies targeting surface antigens, small molecular inhibitors targeting oncogenic signalling pathways and tumour suppressors, and immune checkpoint inhibitors. Chimeric antigen receptor (CAR) T-cells offer the potential for personalised therapy. The emergence of so many new therapeutic options have raised challenges in terms of optimal sequencing and combined approaches, and have highlighted the need for biomarkers to predict therapeutic response.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Lymphoma Content

    Haematological Malignancies, Haematology, Lymphoma
    touchEXPERT OPINIONS
    New and emerging strategies for managing patients with relapsed/refractory follicular lymphoma: latest advances in prognostics and treatment
    CME ACCREDITED Prof. Kami Maddocks, Dr Connie Lee Batlevi, Dr Laurie Sehn Watch Time: 40 mins

    Watch leading lymphoma specialists provide updates on prognostic factors and novel treatment strategies for patients with relapsed/refractory follicular lymphoma

    Learning objectives
    Learning Objectives
    • Evaluate the key prognostic factors that indicate high risk of inferior outcomes in patients with FL
    • Evaluate novel and emerging treatment strategies for patients with R/R FL
    • Translate the latest clinical data for EZH2 and PI3K inhibitors in patients with R/R FL into clinical practice
    Haematological Malignancies, Immunotherapy, Leukaemia, Lymphoma
    touchPANEL DISCUSSION
    What is the current state of play of CAR T-cell therapy for B-cell malignancies? Focus on patient selection, safety and new indications
    Prof. Christian Chabannon, Prof. Chiara Bonini, Prof. Dr. Peter Borchmann Watch Time: 45 mins Available in:

    Learn about patient selection for chimeric antigen receptor (CAR) T-cell therapy, adverse event management and the latest developments in CAR T-cell therapies for B-cell malignancies from experts in the field.

    Learning objectives
    Learning Objectives
    • Describe patients who may be eligible for treatment with CAR T-cell therapy
    • Review the management of adverse events associated with CAR T-cell therapy
    • Discuss how CAR T-cell therapy might impact the treatment pathway for new indications
    Haematological Malignancies, Immunotherapy, Leukaemia, Lymphoma
    touchEXPERT OPINIONS
    Optimizing care with CAR T-cell therapy now and in the future for patients with B-cell malignancies
    Prof. Catherine Thieblemont, Prof. Dr. Marion Subklewe, Dr Maeve O’Reilly, Prof. Adriana Balduzzi, Dr Michael Dickinson Watch Time: 58 mins Available in:

    Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.

    Learning objectives
    Learning Objectives
    • Recall the latest clinical trial and real-world data for CAR T-cell therapies in the management of B-cell malignancies
    • Describe which patients are eligible for CAR T-cell therapy and discuss the optimal time for referral
    • Discuss the safety profile of CAR T-cell therapy and the associated management strategies
    • Describe data for new and emerging indications for CAR T-cell therapy
    Lymphoma
    touchPANEL DISCUSSION
    CAR-T in clinical practice: Navigating the patient journey from referral to long-term follow-up
    Prof. Mohamad Mohty, Dr John Kuruvilla, Dr Robin Sanderson Watch Time: 32 mins

    Watch a panel of internationally renowned experts discuss the use of chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma (DLBCL).

    Learning objectives
    Learning Objectives
    • Recall the latest real-world evidence for the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL)
    • Describe which patients with DLBCL should be referred for assessment for CAR-T therapy and discuss the importance of early referral
    • Discuss the roles of referral centres and treatment centres in patient management, in particular long-term follow up of patients
    Lymphoma
    Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care
    Theodoros P Vassilakopoulos, Boris Böll

    European Oncology and Haematology. 2019:15(1):53–63 DOI: https://doi.org/10.17925/EOH.2019.15.1.53

    Hodgkin lymphoma is a B-cell lymphoma that predominantly affects adults between 20–40 years of age, with a second incidence peak in those 55 years of age or older.1,2 It is also the most common form of lymphoma in adolescents, occurring in nearly two-thirds of patients with lymphoma between the ages of 15–19.3 Overall, the annual incidence of […]

    Lymphoma
    Chimeric Antigen Receptor T-cell Therapy for Relapsed or Refractory Large B-cell Lymphoma – Latest Data from the ZUMA-1 Study
    Javier Munoz

    European Oncology & Haematology, 2019;15(1):16–7 DOI: https://doi.org/10.17925/EOH.2019.15.1.16

    Large B-cell lymphoma includes diffuse large B-cell lymphomas, primary mediastinal B-cell lymphoma and transformed follicular lymphoma. These have historically been treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). High-dose salvage chemotherapy and autologous stem-cell transplantation (SCT) can be used in case of relapse, however, patients who fail R-CHOP or relapse following SCT have a […]

    Haematological Malignancies, Lymphoma
    Theodoros P Vassilakopoulos, MD, PhD, EHA 2019 – Exciting new developments in Hodgkin lymphoma

    At the EHA conference in Amsterdam we are joined by Professor Theodoros P Vassilakopoulos to discuss the most exciting new developments in standards of care for Hodgkin lymphoma. Questions 1. What are the limitations of current standards of care for Hodgkin lymphoma (HL)? (0:05) 2. What is the role of brentuximab vedotin in the current […]

    Lymphoma
    Andrea Gallamini, EHA 2019 – Three-year Update of the ECHELON-1 Study

    We are joined by Andrea Gallamini, at EHA 2019 to discuss his presentation on frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Questions 1. Could you tell us a little about the ECHELON-1 study and its findings? (0:05) 2. What have we learned from the 3-year […]

    Lymphoma
    Eva Domingo Domènech, EHA 2019 – The Phase II CHECKMATE 205 Study

    We are joined by Eva Domingo Domènech at EHA 2019 to discuss her presentation on nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: 2-year extended follow-up from cohort D of the phase II CHECKMATE 205 study. Questions 1. What are the major unmet needs in the treatment of advanced stage […]

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72